- Folate Binding Protein Phase 1/2 trial on track for results in 2013.
- Composition of Matter and Treatment patent covers Folate Binding Protein (FBP) peptide variants for individual or expanded use in combination with the novel FBP vaccine, E39.
- Provides exclusivity in Japan until 2022, with additional worldwide patent filings pending.
Endometrial cancer is the most common gynecologic cancer and occurs in over 46,000 women, with over 8,000 deaths, in the U.S. annually. There are two basic types of endometrial cancer: endometriod and papillary serous. The latter has a much more aggressive clinical course and the majority of these patients will die of this form of the disease.About Galena Biopharma Galena Biopharma, Inc. (Nasdaq:GALE) is a Portland, Oregon-based, biopharmaceutical company that develops innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care. For more information please visit us at www.galenabiopharma.com. The Galena Biopharma, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=10647 Forward-looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 . Such statements include, but are not limited to, statements about the significance of the allowed patent. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including the risks set forth in Galena's most recent annual report on Form 10-K and quarterly reports on Form 10-Q.
CONTACT: Madeline Hatton Toll-free: +1 (855) 855-GALE (4253), ext. 109 email@example.com or Remy Bernarda IR Sense, LLC +1 (503) 400-6995 firstname.lastname@example.org